Novel drug development platform targeting central nervous system diseases. Platform has generated dozens of drug leads with clinical trials underway in Tourette’s Syndrome, MS and Agitation in Alzheimer’s Patients.  Cardinal Partners is  founding investor.  May 2019 – Acquired by Denmark’s H. Lundbeck A/S.